In a letter published in RMD Open, CITF-funded researchers found that SARS-CoV-2 antibody levels and T cell responses increased following a third dose of vaccine in immunocompromised patients. Drs. Vinod Chandran, Anne-Claude Gingras, and Tania Watts (University of Toronto) showed that 92% of COVID-naïve patients with immune-mediated inflammatory disease (IMID) showed anti-spike and anti-RBD antibody levels that were greater than convalescent individuals (those recovering from COVID-19 infection).